Why the study?
Does high-dose verapamil plus adriamycin improve objective response in patients with refractory ovarian cancer?
Does high-dose verapamil plus adriamycin improve objective response in patients with refractory ovarian cancer?
The use of high-dose verapamil to reverse adriamycin resistance in refractory ovarian cancer is limited by unacceptable cardiac toxicity and lack of objective response.
No takes yet. Share an insight, caveat, or question.
High-dose verapamil plus adriamycin yields no responses and unacceptable cardiac toxicity; leaves open whether alternative resistance modulators merit study in refractory ovarian cancer.
Ozols et al. (1987) studied this question.